Recruiting Phase 1 NCT06143527

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS

Trial Parameters

Condition Polycystic Ovary Syndrome (PCOS)

Sponsor The Foundation for Orthopaedics and Regenerative Medicine

Study Type INTERVENTIONAL

Phase Phase 1

Enrollment 20

Sex FEMALE

Min Age 18 Years

Max Age N/A

Start Date 2023-11-16

Completion 2027-11-16

All Conditions

Polycystic Ovary Syndrome (PCOS) Polycystic Ovary Syndrome PCOS

Interventions

AlloRx

Brief Summary

This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.

Eligibility Criteria

Inclusion Criteria: • Ultrasound documented poly cystic ovary syndrome Exclusion Criteria: * Active infection * Active cancer * Chronic multisystem organ failure * Pregnancy * Clinically significant abnormalities on pre-treatment laboratory evaluation * Medical condition that would (based on the opinion of the investigator) compromise patient's safety * Continued drug abuse * Previous organ transplant * Hypersensitivity to sulfur * Inability to supply proper informed consent

Related Trials

NCT05394142

A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of S

View Trial →

NCT06143527

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE POLYCYSTIC OVARY SYNDROME (PCOS) TRIALS